WWE Signs Three New International Talents );
WWE sent out the following press release today, announcing that they’ve signed three new international talents who will be reporting to the WWE Performance Center in Orlando, FL. The company recently signed Feicheng Wang, Sean Tan, and Jie Yin, which you can learn more about below:
International recruits report to WWE Performance Center
A new group of recruits from Asia have reported for training at the WWE Performance Center in Orlando, Fla. );
Feicheng Wang stands 6-foot-2 and weighs 242 pounds. The Chinese recruit was trained for the ring by former WWE PC coach Hartley Jackson and Japanese wrestler and mixed martial artist Alexander Otsuka.
3 New WWE Signings Confirmed
whatculture.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from whatculture.com Daily Mail and Mail on Sunday newspapers.
WWE Introduces Three New International Recruits
ringsidenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ringsidenews.com Daily Mail and Mail on Sunday newspapers.
E-Mail
BOSTON - Many patients with cancer receive immune checkpoint inhibitors that strengthen their immune response against tumor cells. While the medications can be life-saving, they can also cause potentially life-threatening side effects in internal organs. This double-edged sword makes it challenging for clinicians to decide who should be considered candidates for treatment. A new analysis led by researchers at Massachusetts General Hospital (MGH) indicates which patients are at elevated risk of side effects severe enough to require hospitalization. The findings are published in the Understanding the risk factors for predicting high-grade toxicities will help in appropriately selecting patients most likely to tolerate immune checkpoint inhibitor therapy, says co-senior author Yevgeniy R. Semenov, MD, an investigator in the Department of Dermatology at MGH. It will also help to identify higher risk patients who should be carefully monitored if they initiate this therapy.